News | Breast Imaging | August 08, 2016

FDA Breast Imaging Panel Discusses New Ways to Better Assess Mammography Quality

Dense breast tissue’s impact on exam quality will be discussed

dense breast tissue, dense breast imaging, BIRADS, BI-RADS, mammography grading system, comparison of dense breast tissue, Fibroglandular densities

August 8, 2016 — The U.S. Food and Drug Administration’s (FDA) National Mammography Quality Assurance Advisory Committee is considering new measures to improve breast imaging quality and how breast density impacts exams. The panel will discuss these and other items at its next meeting Thursday, Sept. 15, 2016, in Gaithersburg, Md.

The committee provides advice and recommendations to the FDA on agency’s regulatory issues.

The committee will discuss and make recommendations on compliance analysis, focusing on the Mammography Quality Standards Act (MQSA) current compliance trends. The discussion will include trends seen in the analysis, why the trends may be occurring and possible actions that should be sought.     

The panel will also discuss the Inspection Enhancement Project, which is proposes to use the inspection program to enhance breast image quality. FDA is seeking committee input on anticipated facility questions related to the proposal. The approved alternative standard American College of Radiology Full Field Digital Mammography Quality Control Manual contents will be explained and FDA will ask the committee's  advice on facility roll-out strategies.     

The committee will also address issues related to breast density (fibroglandular densities). A presentation will examine the current issues, followed by a committee discussion on how these issues might effect a possible MQSA requirement for reporting breast density.  Future challenges for MQSA include the role of synthesized 2-D images created from 3-D tomosynthesis mammography datasets. The FDA is seeking committee input on this challenge, as well as what future challenges MQSA might encounter.   

Read more about MQSA Mammography Facility Inspector Training. 

For more informtion: www.fda.gov/AdvisoryCommittees/Calendar/ucm515098.htm

 

Related Content

Christopher Comstock, M.D., ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

Christopher Comstock, M.D., (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half times as many) breast cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breasts. Photo courtesy of Memorial Sloan Kettering Cancer Center

News | Breast Imaging | February 26, 2020
February 26, 2020 — According to a study
Women 75-plus May Not Benefit from Breast Cancer Screening
News | Mammography | February 25, 2020
February 25, 2020 — According to newly published research in an article titled...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...